Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/29364
Title: The Plant Proteinase Inhibitor CrataBL Plays a Role in Controlling Asthma Response in Mice
Authors: BORTOLOZZO, Anelize Sartori SantosRODRIGUES, Adriana Palmeira DiasARANTES-COSTA, Fernanda MagalhaesSARAIVA-ROMANHOLO, Beatriz MangueiraSOUZA, Flavia Castro Ribas deBRUGGEMANN, Thayse ReginaBRITO, Marlon Vilela deFERREIRA, Rodrigo da SilvaCORREIA, Maria Tereza dos SantosPAIVA, Patricia Maria GuedesPRADO, Carla MaximoLEICK, Edna AparecidaOLIVA, Maria Luiza VilelaMARTINS, Milton de ArrudaRUIZ-SCHUTZ, Viviane ChristinaRIGHETTI, Renato FragaTIBERIO, Iolanda de Fatima Lopes Calvo
Citation: BIOMED RESEARCH INTERNATIONAL, article ID 9274817, 15p, 2018
Abstract: Background. CrataBL is a protein isolated from Crataeva tapia bark. It has been shown to exhibit several biological properties, including anti-inflammatory, analgesic, antitumor, and insecticidal activities. There are no studies evaluating the role of CrataBL in experimental asthma models. Aim. To evaluate the effects of CrataBL on lung mechanics, inflammation, remodeling, and oxidative stress activation of mice with allergic pulmonary inflammation. Materials and Methods. BALB/c mice (6-7 weeks old, 25-30g) were divided into four groups: nonsensitized and nontreated mice (C group, n=8); ovalbumin- (OVA-) sensitized and nontreated mice (OVA group, n=8); nonsensitized and CrataBL-treated mice (C+CR group, n=8); OVA-sensitized and CrataBL-treated mice (OVA+CR group, n=8). We evaluated hyperresponsiveness to methacholine, bronchoalveolar lavage fluid (BALF), pulmonary inflammation, extracellular matrix remodeling, and oxidative stress markers. Results. CrataBL treatment in OVA- sensitized mice (OVA+CR group) attenuated the following variables compared to OVA- sensitized mice without treatment (OVA group) (all p<0.05): (1) respiratory system resistance (Rrs) and elastance (Ers) after methacholine challenge; (2) total cells, macrophages, polymorphonuclear cells, and lymphocytes in BALF; (3) eosinophils and volume fraction of collagen and elastic fibers in the airway and alveolar wall according to histopathological and morphometry analysis; (4) IL-4-, IL-5-, IL-13-, IL-17-, IFN-gamma-, MMP-9-, TIMP-1-, TGF-beta-, iNOS-, and NF-kB-positive cells and volume of 8-iso-PGF2 in airway and alveolar septa according to immunohistochemistry; and (5) IL-4, IL-5, and IFN-according to an ELISA. Conclusion. CrataBL contributes to the control of hyperresponsiveness, pulmonary inflammation, extracellular matrix remodeling, and oxidative stress responses in an animal model of chronic allergic pulmonary inflammation.
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MCM
Departamento de Clínica Médica - FM/MCM

Artigos e Materiais de Revistas Científicas - FM/MPT
Departamento de Patologia - FM/MPT

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - LIM/20
LIM/20 - Laboratório de Terapêutica Experimental


Files in This Item:
File Description SizeFormat 
art_BORTOLOZZO_The_Plant_Proteinase_Inhibitor_CrataBL_Plays_a_Role_2018.PDFpublishedVersion (English)6.81 MBAdobe PDFThumbnail
View/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.